Why Chiron May Be On The MendBy
Chiron (CHIR), like most other biotechs, has yet to recover from its big fall in March. The stock plunged from 67, hitting 34 in May--and is currently at 44. But "recovery should accelerate from now on," predicts James McCamant, editor of Medical Technology Stock Letter in Berkeley, Calif.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.